Candy with Mushroom Micro-Dosing Recalled After Making Dozens Sick in 20 States!

Prophet Premium Blends, a California-based company specializing in micro-dosing products, is issuing a nationwide recall following reports of illness linked to its Diamond Shruumz-infused cones, chocolate bars, and gummies. The U.S. Food and Drug Administration (FDA) has identified muscimol, a psychoactive compound found in certain mushrooms of the Amanita genus, as the likely cause of illness among consumers in 20 states, including New York.

The recall affects products distributed widely across the country, raising concerns about the safety and regulation of psychedelic-infused edibles. Muscimol, known for its hallucinogenic properties, can induce symptoms such as nausea, vomiting, confusion, and, in severe cases, neurological effects. The FDA advises consumers who have purchased these products to refrain from consuming them and to contact their healthcare providers if they experience any adverse reactions.

This incident underscores the challenges faced by regulatory agencies in overseeing the burgeoning market of micro-dosing products, which often operate in a legal gray area due to varying state laws on psychedelic substances. While micro-dosing—taking sub-perceptual doses of psychedelics like mushrooms—has gained popularity for purported therapeutic benefits, the safety of commercially produced infused products remains a concern.

Prophet Premium Blends has initiated the recall voluntarily in cooperation with the FDA and state health authorities. Customers are urged to return the recalled products to the point of purchase for a refund or disposal. The company has pledged to enhance its quality control measures to prevent similar incidents in the future, emphasizing consumer safety as a top priority amid growing interest in psychedelic therapies.

Read More:

Health officials continue to monitor the situation closely, advising consumers to exercise caution when purchasing and consuming micro-dosing products, particularly those lacking clear regulatory oversight. The FDA encourages anyone experiencing symptoms after consuming these products to report their cases through its MedWatch program, contributing to ongoing efforts to safeguard public health.